DRUGS REPURPOSING FOR HEART FAILURE - COMPUTATIONAL APPROACHES TARGETING SGLT2
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest approved treatment for heart failure (HF), demonstrating a significant reduction in cardiovascular outcomes associated with this condition. Based on the increasing prevalence of HF and the urgent demand for safer and more effective therapeutic options, this study employed in silico approaches to systematically screen a comprehensive library of conventional drugs for their binding affinity to the SGLT2 protein. Materials and methods: More than 70 drugs, belong to several chemical and pharmacological classes, such as proton pump inhibitors, oral hypoglycemic drugs (sulfonylureas, gliptins), statins, nonsteroidal anti-inflammatory drugs, H1/H2 antagonists, antineoplastic drugs, alfa-adrenergic agonists, vitamins, antioxidants, were screened for their SGLT2 affinity using molecular docking method. In addition, for the drugs with the best docking score, a pharmacokinetic profile prediction using computational tools was also performed. Canagliflozin, empagliflozin and dapagliflozin were used as SGLT2 reference inhibitors. Results and discussion: The docking simulations revealed that the binding of the ligands to SGLT2 involves direct hydrogen bonds and van der Waals interactions with amino acids in the active site, such as H80, G83, L84, F98, E99, V85, V157, K154, L283, V286, V287, Y290, W291 and Q457. The best docking score, much better than SGLT2 reference inhibitors, was obtained for sulfonylureas (gliquidone, glipizide, glibenclamide, glimepiride), statins (atorvastatin, simvastatin), rutin and vitamins (vitamin K and E). Conclusions: Based on in silico results, in term of affinity for SGLT2 and pharmacokinetic profile prediction, several drugs show theoretical potential for beneficial effects in HF and could be considered for further investigation in advanced studies to validate these findings.
References
1. Khan MS, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J. Global epidemiology of heart failure. Nat Rev Cardiol 2024; 21(10): 717-34.
2. Lund LH, Crespo-Leiro MG, Laroche C, Zaliaduonyte D, Saad AM, Fonseca C, et al. Heart failure in Europe: Guideline‐directed medical therapy used and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry. Eur J Heart Fail 2024; 39257278: 1-15.
3. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-3726.
4. Steiner B, Neumann A, Plez Y, et al. Challenges in heart failure care in four European countries: a comparative study. Eur J Public Health 2023; 33(3): 448-454.
5. Bozkurt B, Ahmad T, Alexander K, et al. HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics an Updated 2024 Report from the Heart Failure Society of America. J Card Fail 2024; 39322534.
6. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023; 118(17): 3272-3287.
7. Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update. Circulation 2021; 143(8): 2254-e743.
8. Lorenzovici L, Bârzan-Székely A, Farkas-Ráduly S, et al. Burden of Chronic Heart Failure in Romania. Healthcare 2022; 10(1): 107.
9. Espriella R, Santas E, Zegri Reiriz I, Górriz JL, Cobo Marcos M, Núñez J. Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview. Nefrología 2022; 42(2): 145-162.
10. Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in heart failure: A review of current evidence. Int J Heart Failure 2023; 5(2): 82-90.
11. Shah KS, Fang JC. Sodium-glucose cotransporter 2 Inhibitors in heart failure. Annu Rev Pharmacol Toxicol 2022; 62(1): 109-120.
12. Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia 2018; 61(10): 2087-2097.
13. Abdelsayed M, Kort EJ, Jovinge S, Mercola M. Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat Rev Cardiol 2022; 19(11): 751-764.
14. Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand dock-ing and virtual drug screening with the AutoDock suite. Nat Protoc 2016; 11(5): 905-919.
15. Rizvi SMD, Shakil S, Haneef M. A simple click by click protocol to perform docking: Auto Dock 4.2 made easy for non-bioinformaticians. EXCLI J 2013; 12: 831-857.
16. Niu Y, Liu R, Guan C, et al. Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter. Nature 2022; 601(7892): 280-284.
17. Chandrasekaran B, Abed SN, Al-Attraqchi O, Kuche K, Tekade RK. Computer-Aided Prediction of Pharmacokinetic (ADMET) Properties. In: Dosage Form Design Parameters: Advances in Pharma-ceutical Product Development and Research, vol II, Academic Press, 2018, 731-755.
18. Shakya AK, Al-Najjar BO, Deb PK, Naik RR, Tekade RK. First-Pass Metabolism Considerations in Pharmaceutical Product Development. In: Dosage Form Design Parameters: Advances in Pharma-ceutical Product Development and Research, volume I, Academic Press, 2018, 259-286.
19. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015; 58(9): 4066-4072.

Additional Files
Published
Issue
Section
License
Copyright (c) 2024 The Medical-Surgical Journal

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form